Osiris Therapeutics competitorsClear all

Osiris Therapeutics's top competitors include GenSight Biologics, Immusoft, Reneuron Group and Eloxx Pharmaceuticals.
Osiris Therapeutics
Osiris Therapeutics
Osiris Therapeutics researches, develops, manufactures, markets, and distributes regenerative medicine products in the United States.
GenSight Biologics
GenSight Biologics
GenSight Biologics develops gene therapy-based treatments for retinal degenerative diseases.
Immusoft
Immusoft
Immusoft is a biotechnology company commercializing technologies that program the human immune system by modifying the DNA in related cells.
Reneuron Group
Reneuron Group
ReNeuron Group engages in R&D and the commercial exploitation of stem cell technologies for therapeutic and non-therapeutic applications.
Eloxx Pharmaceuticals
Eloxx Pharmaceuticals
Eloxx Pharmaceuticals is a clinical-stage biopharmaceutical company developing treatments for rare and ultra-rare genetic diseases.
Founding Date
Founding Date
1992
Founding Date
2011
Founding Date
2009
Founding Date
1997
Founding Date
2013
Type
Type
Public
Type
Public
Type
Private
Type
Public
Type
Public
Tags
Locations
Locations
Columbia, US HQ
Locations
Paris, FR HQ
New York, US
Locations
Seattle, US HQ
Locations
Surrey Research Park, GB HQ
Locations
Waltham, US HQ
Rehovot, IL
Employees
Employees
3421% increase
Employees
37
Employees
19
Employees
5320% increase
Employees
2993% increase
Valuation ($)
Valuation ($)
655.7 m
Valuation ($)
118.4 m
Valuation ($)
N/A
Valuation ($)
73.5 m
Valuation ($)
351.2 m
Alexa Website Rank
Alexa Website Rank
527479
Alexa Website Rank
804029
Alexa Website Rank
N/A
Alexa Website Rank
1071527
Alexa Website Rank
N/A

Financial

Revenue (est.)
Revenue (est.)
$142.8m (FY, 2018)
Revenue (est.)
N/A
Revenue (est.)
N/A
Revenue (est.)
£43k (FY, 2018)
Revenue (est.)
N/A
Net income
Net income
$36.9m (FY, 2018)
Net income
N/A
Net income
N/A
Net income
(£17.6m) (FY, 2018)
Net income
($47.2m) (FY, 2018)

Funding

Total funding raised
Total funding raised
$ 65m
Total funding raised
$ 103.1m
Total funding raised
$ 9.4m
Total funding raised
$ 38.4m
Total funding raised
$ 30m
For sources of this data, please see the company profile

View company profiles

GenSight Biologics
HQ
Paris, FR
Employees
37

GenSight Biologics develops gene therapy-based treatments for retinal degenerative diseases.

View company
Immusoft
HQ
Seattle, US
Employees
19

Immusoft is a biotechnology company commercializing technologies that program the human immune system by modifying the DNA in related cells.

View company
Reneuron Group
HQ
Surrey Research Park, GB
Employees
53↑ 20% increase

ReNeuron Group engages in R&D and the commercial exploitation of stem cell technologies for therapeutic and non-therapeutic applications.

View company
Eloxx Pharmaceuticals
HQ
Waltham, US
Employees
29

Eloxx Pharmaceuticals is a clinical-stage biopharmaceutical company developing treatments for rare and ultra-rare genetic diseases.

View company